Arjo cuts forecast as US operations run into trouble
This article was originally published in Clinica
Swedish medical device manufacturer Arjo saw the profitability of its US operation deteriorate during the first half of its fiscal 1995. As a consequence, the president of US operations William Hardy resigned at the beginning of May and has yet to be replaced. The decline in US profitability together with increased competition, particularly in the patient handling field, and difficult conditions in the UK market have caused Arjo to lower its forecast for full fiscal 1995 from previous levels to a "modest improvement in earnings per share".
You may also be interested in...
ConMed Corp. is company of two halves ̶ general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.
Drug pricing and access issues expose the pharmaceutical sector especially acutely to calls for companies to meet ethical and social goals, alongside commercial ones. Digital is up-ending pharma’s processes, its workplaces and its consumers. R&D productivity is spluttering. Amid this turmoil, CEOs highlight company culture – the way an organization behaves – as a crucial ingredient for success. But what is a “right” culture? Organizational culture is neither static nor singular. It is continuously influenced by acquisitions, markets, new technologies and new generations. And pharma’s history suggests that culture change cannot happen without sufficient people change.